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Haptoglobin 2-2 genotype, patient and graft survival in renal 
transplant recipients 
ABSTRACT 
Background. Cardiovascular disease is the leading cause of death in renal transplant recipients 
(RTRs). An association between haptoglobin genotype 2-2 and cardiovascular disease has been 
found in patients with diabetes mellitus and liver transplant recipients. To date, the role of 
haptoglobin genotype after renal transplantation has not been studied.  
Methods. In this single centre retrospective cohort study of 1975 adult Norwegian RTRs, 
transplanted between 1999 and 2011, we estimated the risk of all-cause and cardiovascular 
mortality and overall and death censored graft loss for patients with haptoglobin genotype 2-2 
compared with genotype 2-1 or 1-1, after adjustment for confounders and competing risks.  
Results. We found no associations between haptoglobin genotype 2-2 and cardiovascular 
mortality (subdistributional hazard ratio [SHR] 1.08, 95% confidence interval [CI] 0.78-1.49, 
p=0.63). We also failed to detect any association between haptoglobin 2-2 genotype and all-cause 
mortality, overall graft loss and death censored graft loss. Similar results were found in the 
subpopulation of diabetic RTRs. 
Conclusion. In this large cohort of kidney transplant recipients, we could not demonstrate any 










Cardiovascular disease (CVD) contributes to one third of all premature deaths worldwide1, and is 
the major cause of death in renal transplant recipients (RTRs)2. Oxidative stress induces 
endothelial dysfunction and increases the risk of CVD2,3. Several pro- and anti-oxidative 
pathways act simultaneously, including pathways that make use of haemoglobin (Hb) and its 
detoxifier haptoglobin (Hp). When Hb is released from erythrocytes during intravascular 
hemolysis, Hp binds the free Hb and the Hp-Hb complex is cleared from the circulation by the 
macrophage CD163 receptor4. Free Hb is highly toxic through release of free iron generating 
reactive oxygen species, initiating and enhancing atherosclerosis4. Due to genetic polymorphism; 
Hp 1-1, 2-1, and 2-2 genotype, Hp proteins are functionally different in different individuals4. Hp 
2 proteins are not cleared from the circulation by the macrophage CD163 receptor as efficiently 
as Hp 1 proteins4. Consequently, individuals with the Hp 2-2 genotype are less protected against 
Hb-induced oxidative damage than individuals expressing Hp 1-1 or 2-1 genotypes5. In addition 
to Hp-Hb complex clearance by macrophages, renal proximal tubule cells can also clear the Hp-
Hb complex6. However, renal clearance of the Hp-Hb complex may cause increased iron 
concentration in the proximal tubular cells, leading to tubular damage, collagen deposition and 
ultimately fibrosis. This mode of clearance mostly occurs in Hp 2-2 genotype individuals due to 
their lower macrophage CD163 receptor clearance4.   
 
The most compelling evidence for a role of Hp genotype in cardiovascular health has been found 
in both human and animal studies of diabetes mellitus4,7. In transplant medicine, the role of Hp 
genotype has scarcely been studied. In liver transplant recipients, donor Hp 2-2 genotype was 
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associated with reduced patient and graft survival8. To the best of our knowledge, no previous 
study has assessed associations between Hp genotype and patient and graft survival after renal 
transplantation.  
 
The aim of the present study was to investigate the association between Hp 2-2 genotype and 
cardiovascular mortality, after adjustment for confounders and competing risk from other causes 
of death. In addition, we assessed associations between Hp 2-2 genotype and all-cause mortality, 
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PATIENTS AND METHODS 
Study participants, design, endpoints, data collection and procedures 
From a total of 2746 consecutive patients who received a renal transplant at Oslo University 
Hospital Rikshospitalet, Norway between 30th of September 1999 and 13th of October 2011, data 
on Hp genotype were available in 1975 patients. Baseline differences between included and not 
included study participants has been described elsewhere9,10. In short, adult patients not included 
in the study were older than the study participants. When stratifying for age categories, study 
participants more often had a living donor. Otherwise there were no significant differences 
between the two groups. Informed consent was obtained from all patients. Selection of study 
patients, data quality control, handling of missing data, fitting of regression models, definition of 
outcomes and the standard immunosuppressive protocol in this cohort have previously been 
described in detail9. Clinical data were extracted from patient records. Endpoint data were 
provided by The Norwegian Renal Registry, which is based upon annual reports from all 
nephrology units and includes all patients on renal replacement therapy in Norway. Overall renal 
graft loss included both grafts lost due to recipient death and death censored graft loss (return to 
dialysis and renal re-transplantation). There were less than 1% missing data for included patients. 
The immunosuppressive therapy consisted of a combination of prednisolone, a cell proliferation 
inhibitor and a calcineurin inhibitor (cyclosporine A or tacrolimus), with some minor variations 
in what drugs have been used during the study period. Induction therapy with basiliximab was 
given to all patients transplanted in the year 2000 and from 2007 to 2011. Acute rejections were 
treated with intravenous methylprednisolone followed by an increased dose of oral prednisolone 
which was tapered over the following two months. Steroid-resistant rejections were treated with 
anti-thymocyte globulin or anti-CD3 monoclonal antibodies.  
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Hp genotypes were determined using high-performance liquid chromatography (HPLC) at 
Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Denmark. 
We used a modified HPLC method as previously described11,12. In brief, HPLC was performed 
using an UltiMate 3000 pump, an UltiMate 3000 autosampler, an UltiMate 3000 Variable 
Wavelength Detector (Dionex Denmark A/S, Hvidovre, Denmark) and a HPLC system manager 
(Chromeleon Client version 6.80, Dionex Corporation, Sunnyvale, CA, USA). For 
chromatographic separation, a YarraTM 3 µm SEC-3000 column (Phenomenex®, Værløse, 
Denmark) was used. To vials containing 30 µL plasma, 5 µL haemoglobin solution (dilution 
1:10) and subsequently, 1255 µL PBS solution were added as the mobile phase. The flow rate 
was 1 ml/min. Detection of the haptoglobin-haemoglobin complex elution was monitored at 
wavelength 418 nm. We used human reference plasma with known Hp phenotype (H1511 pooled 
plasma, H0138 Hp 1-1, and H9762 Hp 2-2. SIGMA, Sigma-Aldrich Denmark a/s, Denmark) for 
comparison. Hp phenotype was determined from the curve shape and the relative retention time 
of the chromatograms. 
 
Statistical analysis 
Chi-square test, independent t-test and Mann-Whitney U-test evaluated differences in patient 
characteristics at the time of transplantation between patients with Hp 2-2 genotype and Hp 2-1 
or 1-1 genotype as appropriate (Table 1).  
 
The two main statistical approaches in the present study were a proportional hazard regression 
model for the subdistribution of competing risks13,14 with either time to death censored graft loss 
or cardiovascular mortality as the outcome variable, and standard Cox regression with all-cause 
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mortality or overall renal graft loss as the outcome variable. The observational time started at the 
time of transplantation. Surviving patients were censored at 1st January 2015. In addition to Hp 
genotype, the following pre-defined variables were included in the model: Recipient age, gender, 
donor age, current smoking, atherosclerotic disease (coronary artery disease, cerebrovascular 
disease and/or peripheral vascular disease), transplant era (year 1999 through 2006 versus year 
2007 through 2011), first or previous renal transplantation, living or deceased donor, preemptive 
transplantation, time in dialysis therapy prior to transplantation, diabetes mellitus prior to 
transplantation or posttransplantation diabetes mellitus during the first year after transplantation, 
and type of calcineurin inhibitor (cyclosporine A or tacrolimus) used at ten weeks after 
transplantation. We also performed similar analyses in a subgroup consisting of patients that were 
diagnosed with post-transplantation diabetes mellitus during the first year after renal 
transplantation or had diabetes prior to transplantation (n=470).  
 
In addition, we assessed differences in biopsy proven acute rejection rates, as previously 
described9, between Hp genotypes. For 156 patients transplanted during 2010, we had available 
data on histologically verified progression of fibrosis between six weeks and one year post-
transplant15. The proportion of progressors and non-progressors in each Hp genotype was 
compared. A two-sided p-value <0.05 was considered statistically significant.  
The study was approved by the Regional Committees for Medical and Health Research Ethics in 








Demographic and clinical characteristics of the study population are presented in Table 1. No 
differences between the Hp 2-2 genotype group and the pooled Hp 2-1 and 1-1 genotype group 
were found.  
During a median follow-up of 7.0 (interquartile range = 4.7 – 10.5) years, there were 401 deaths, 
either due to cardiovascular disease (n=156) or other causes (n=245). A total of 568 renal grafts 
were lost, either due to recipient death (n=335) or death censored graft loss (n=233). 
Mortality 
After adjustment for potential confounders and competing risk from other causes of death, 
patients with Hp 2-2 genotype did not have an increased cardiovascular mortality risk compared 
with RTRs with Hp 1-1/2-1 genotype (subdistributional hazard ratio [SHR] 1.08, 95% confidence 
interval [CI] 0.78-1.49, p=0.63) (Table 2). Lack of association between Hp 2-2 genotype and 
cardiovascular mortality was also found in a subgroup analysis of RTRs with diabetes prior to 
transplantation or post-transplantation diabetes (SHR 1.06, 95% CI 0.58-1.95, p=0.84). In 
addition, we did not find an association between Hp 2-2 genotype and all-cause mortality in the 
whole study population (hazard ratio [HR] 0.93, 95% CI 0.79-1.10, p=0.41) or diabetic RTRs 
(HR 0.99, 95% CI 0.69-1.44, p=0.98). 
Renal graft loss 
RTRs with Hp 2-2 genotype had no increased risk of overall graft loss (HR 0.92, 95% CI 0.78-
1.09, p=0.34). Similarly, we found no association between Hp 2-2 genotype and death censored 
graft loss (SHR 0.95, 95% CI 0.73-1.24, p=0.72). In RTRs with diabetes, there were no 
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statistically significant association between Hp 2-2 genotype and overall graft loss (HR 0.76, 
95% CI 0.55-1.06, p=0.11) or death censored graft loss (SHR 0.61, 95% CI 0.34-1.07, p=0.09). 
There were no differences in choice of immunosuppressive regimens between Hp genotypes 
(data not shown). Rates of biopsy proven acute rejection episodes were similar in Hp 2-2 
genotype as in Hp 1-1 and 2-1 genotypes both in early phase (first ten weeks after renal 
transplantation) and beyond the early post-transplant phase (data not shown). The proportion of 
patients with histologically verified progression of fibrosis during the first year post-transplant 
















The present study found no association between Hp 2-2 genotype and cardiovascular mortality, 
all-cause mortality, overall renal graft loss or death censored graft loss. The distribution of Hp 
genotype was similar to previous studies (Hp 1-1: 13.2%, Hp 2-1: 44.5%, Hp 2-2: 42,3%)16,17. 
Haptoglobin genotype and CVD 
Hp genotype is one of several factors that might induce oxidative mediated atherosclerosis, and 
its role in the development of CVD is not clearly established4. Hp 2-2 genotype is positively 
associated with myocardial infarction size 18 and negatively associated with coronary bypass graft 
patency19. However, most studies in non-diabetic patients have reported neutral4 or even 
beneficial associations with Hp 2-2 genotype20. In patients with diabetes, the evidence for an 
association between Hp 2-2 genotype and CVD is stronger. Macrophage clearance of the Hp-Hb 
complex is slower in Hp 2-2 genotype individuals21, leaving more glycated Hb and reactive 
oxygen species in the circulation. A positive association between Hp 2-2 genotype and the risk of 
major cardiac events were found in the Strong Heart Study17 and The Munich Stent study16, and 
supplementation of the anti-oxidant vitamin E lowered the risk of cardiovascular events in 
diabetic patients with Hp 2-2 genotype in the ICARE study22.  
In the present study, we found no association between Hp 2-2 genotype and cardiovascular 
mortality, even not in the subgroup of diabetic patients. It should be noted, however, that 
associations with mortality endpoints, being crude outcome variables, would not necessarily 
reflect possible associations between Hp 2-2 genotype and cardiovascular morbidity, including 
major cardiovascular events. Indeed, previous reports indicate a positive association between Hp 
2-2 genotype and development of CVD, while a similar association with cardiovascular mortality 
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has not been shown. Moreover, Hp 2-2 genotype is linked to atherosclerosis. There was a 
significant association between atherosclerotic disease prior to transplantation and cardiovascular 
mortality. In multivariable adjusted survival analysis, atherosclerotic disease prior to 
transplantation was introduced as a confounding variable, while it could also partly be an 
intermediate variable linking Hp 2-2 genotype to cardiovascular mortality. On the other hand, in 
univariate analyses, similar associations were found between Hp 2-2 genotype to cardiovascular 
mortality. Unfortunately, we did not have any data on cardiovascular events in this cohort. 
Haptoglobin genotype and kidney disease  
Previous reports indicate a positive association between Hp 2-2 genotype and decline in renal 
function and end-stage renal disease incidence in patients with diabetes23,24. Glomerular filtration 
of Hp 2-2 proteins increases iron deposition in and damage to renal proximal tubule cells6. In 
patients with end-stage renal disease, Hp 2-2 genotype was associated with higher high-sensitive 
C-reactive protein levels25, indicating a relationship between Hp genotype and inflammation. We 
found no association between Hp 2-2 genotype and overall or death censored graft loss. Although 
most of the Hp proteins are synthesized in the liver, where the recipient genotype determines the 
Hp protein product, there is some production of Hp proteins in the kidney, which for RTRs will 
be determined by the donor Hp genotype. Obviously, this may prelude any associations between 
recipient Hp genotype and renal graft survival. 
Haptoglobin genotype and organ transplantation  
In transplant medicine, only a few studies have investigated the role of Hp genotype. In liver 
transplant recipients, embracing 450 patients during 3 years follow-up, donor Hp 2-2 genotype 
compared with donor Hp 2-1 and 1-1 genotypes was associated with poorer patient and graft 
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survival8. Haptoglobin is predominantly synthesized by hepatocytes, hence donor Hp genotype 
determines which Hp protein will be produced in this patient group8. In heart transplant 
recipients, Hp 2-1 genotype, but not Hp 2-2 genotype, was associated with a higher risk of 
cardiac transplant vasculopathy26. Due to a small sample size this finding should be interpreted 
with caution and the biological rationale for an association between Hp 2-1 genotype and cardiac 
transplant vasculopathy remains unexplained. In RTRs, Hp 1-1 genotype compared with Hp 2-2 
and 2-1 genotype was associated with increased risk for development of cutaneous squamous cell 
carcinoma27. To date, the roles of either recipient or donor Hp genotype for most long-term 
outcomes after renal transplantation has not been investigated, including patient and graft 
survival.  
Strengths and limitations 
The major strength of the present study is the large cohort from a single center with only a few 
missing data. The present study also has several limitations, some of which has been addressed in 
previous sections. We have no information about donor Hp genotype. The study population 
almost exclusively consisted of Caucasian patients and the results may therefore not apply to 
other ethnical groups. Since haptoglobin genotyping was only performed in patients who 
attended a clinical visit ten weeks after renal transplantation, the survival analyses might have 
been influenced hampered by immortal time bias to some degree. The choice of mortality 
endpoints might have been to crude to detect an impact of Hp genotypes on cardiovascular 
health. Finally, we had no information on pre-existing cardiovascular disease.  
 
 




Recipient Haptoglobin genotype was not associated with either cardiovascular mortality, all-
cause mortality, overall and death censored graft loss after renal transplantation, including renal 
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